Evaluation of an online writing tool based on the CONSORT : a randomized controlled trial

Similar documents
Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)

Guidelines for AJO-DO submissions: Randomized Clinical Trials June 2015

Improving reporting in randomised trials: CONSORT statement and extensions Doug Altman

Current reporting in published research

Reporting guidelines: past, present and future

PEER REVIEW HISTORY ARTICLE DETAILS

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Tatyana A Shamliyan. I do not have COI. 30-May-2012

Protocol registration and outcome reporting bias in randomised controlled trials of

SIGN CRITICAL APPRAISAL COURSE: EXERCISE 2

Submission of a clinical trial for access to ECRIN services Notice to the Applicant

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

Prepared by:jane Healey ( 4 th year undergraduate occupational therapy student, University of Western Sydney

Intervention and clinical epidemiological studies

Cancer Treatments Subcommittee of PTAC Meeting held 18 September (minutes for web publishing)

Random Allocation Software for Parallel Group Randomized Trials

10. Treatment of peritoneal dialysis associated fungal peritonitis

Citation: Robertson, I.H., Gray, J.M., Pentland, B., & Waite, L.J. (1990). Microcomputerbased

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Humulin (LY041001) Page 1 of 1

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

NKR 13 Alkoholbehandling. Disulfiram for alcohol dependency

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Using telehealth to deliver speech treatment for Parkinson s into the home: Outcomes & satisfaction

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

NCT sanofi-aventis HOE901_3507. insulin glargine

Critical Appraisal of Article on Therapy

Assessing study quality: critical appraisal. MRC/CSO Social and Public Health Sciences Unit

Characteristics of studies

Themes. Why is waste in research an ethical issue? Waste occurs in all stages of research. Research funding is finite

The Campbell Collaboration Study content coding Effect size coding (next session)

Richard Schulz, PhD Professor of Psychiatry Director, University Center for Social and Urban Research University of Pittsburgh

Database of randomized trials of psychotherapy for adult depression

Trial Description. Organizational Data. Secondary IDs

Treatment Interventions for Suicide Prevention. Kate Comtois, PhD, MPH University of Washington

(a) the Government s Budget changes relating to mental health;

Form B-1. Inclusion form for the effectiveness of different methods of toilet training for bowel and bladder control

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

Application of Clinical Trial Certificate of Chinese Medicines in Hong Kong

Clinical Study Synopsis

Queensland state schools School Performance Assessment Framework

Managing depression after stroke. Presented by Maree Hackett

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial

The CONSORT (Consolidated Standards of Reporting

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Guidance for Peer Reviewers. The Journal of the American Osteopathic Association (JAOA)

MIND-BODY THERAPIES FOR HYPERTENSION

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation

Eliminating Bias in Randomized Controlled Trials: Importance of Allocation Concealment and Masking

Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device

SYNOPSIS. Risperidone: Clinical Study Report CR003274

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Distance Education as a Training Tool for Health Professionals: Systematic Review and Meta-Analysis of Randomized Trials

Best supportive care: Do we know what it is?

RESEARCH METHODS & REPORTING

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Summary ID# Clinical Study Summary: Study F3Z-JE-PV06

2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.

WHAT ARE THE SPECIFIC DIFFERENCES BETWEEN VERSION 5.5 AND VERSION 5.6 OF THE RESEARCH ETHICS COMMITTEE STANDARD APPLICATION FORM?

C2 Training: June 8 9, 2010

GUIDE TO RANDOMISED CONTROLLED TRIAL PROTOCOL CONTENT AND FORMAT (FOR NON CTIMP S)

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche

Familieorienteret alkoholbehandling versus Individuel alkoholbehandling for

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Hongcai Shang Beijing university of Chinese medicine, China 11-Nov-2015

UCB. Certolizumab pegol (CIMZIA ) for the treatment of Rheumatoid Arthritis PATIENT ACCESS SCHEME (PAS) SUBMISSION TO NICE

Ask Us About Clinical Trials

Clinical bottom line. For more detailed evidence on the effectiveness of injections for tennis elbow, please see the CAT on:

Template for essential information to be provided for proposals including clinical trials / studies / investigations

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

NKR 33 Urininkontinens, PICO 3: Bør kvinder med urininkontinens tilbydes behandling

(4) To characterize the course of illness after adequate response to and continuation on the treatments found effective for individual participants.

Developing an implementation research proposal. Session 2: Research design

Clinical Study Synopsis for Public Disclosure

Randomization in Clinical Trials

BEST in MH clinical question-answering service

Music-Based Interventions and the Resilience of Persons with Dementia

Study Designs. Simon Day, PhD Johns Hopkins University

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental

The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool

Critical appraisal. Gary Collins. EQUATOR Network, Centre for Statistics in Medicine NDORMS, University of Oxford

ChangingPractice. Appraising Systematic Reviews. Evidence Based Practice Information Sheets for Health Professionals. What Are Systematic Reviews?

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

CRITICALLY APPRAISED PAPER (CAP)

First question to ask yourself Do you really need to do a randomised controlled trial (RCT)?

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Defining your PICO Question. In: Patient or Problem or Risk Factor EXAMPLE: Does: Treatment A or Exposure A EXAMPLE: EXAMPLE: Outcome of interest

Cochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment

Authors Checklist for Manuscript Submission to JPP

CLINICAL RESEARCH PROTOCOL CHECKLIST

Clinical Study Synopsis

Clinical Study Synopsis

Transcription:

Evaluation of an online writing tool based on the CONSORT : a randomized controlled trial Philippe Ravaud Ottawa, Oct 16, 2014

Context Despite the existence of the CONSORT guidelines for randomized controlled trials (RCTs) since 1996, inadequate reporting remains 1,2,3 >30% of trial interventions with insufficient descriptions >50% of planned study outcomes not reported Objective: To develop and evaluate the impact of a CONSORT based online writing tool on the completeness of reporting in manuscript drafts 2 1. Glasziou P et al. Lancet. 2014 2. Chalmers I et al. Lancet. 2009 3. Glasziou P et al. BMJ.2008

Methods: Study design Split-manuscript randomized controlled trial design (derived from a split-body design) Methods section was splitted into 6 domains Trial design Randomization Blinding Participants Interventions Outcomes Unit of randomization: domain (3 with the tool and 3 without The randomization sequence was computer generated and the sequence secured by a computer interface 3

4 Masters and doctoral students asked to write the methods section of an RCT based on a study protocol

Methods: Development of the writing tool The theory behind the development of this writing tool was to enforce the use of the guidelines as of the writing of the first draft instead of simply waiting until the submission of the article to journals. The tool included the CONSORT item as well as further elaboration of what the writer should include in order to properly report this item. The information for this further elaboration was taken from the corresponding explanation and elaboration publication of the CONSORT statement. The tool was also developed to take into account the guidelines for reporting randomized controlled trials with non pharmacologic treatments. 5 Finally, examples of adequate reporting were provided for the writers

Methods: Development of the writing tool INTERVENTIONS (Pharmacological treatment) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered Please provide a detailed description of the experimental intervention including the: Medication name Mode of administration Dose and duration Please provide a detailed description of the control intervention:... 6

Methods: Interventions Four hours to write the methods section of an RCT based on a study protocol for articles published in the NEJM or JCO in 2013 Example: domain trial design, experimental and control interventions 7

8 Outcomes and statistical analyses Outcomes: Primary: average score for completeness of reporting Secondary: scores for completeness of reporting by domain, average score for completeness of reporting essential elements Outcome assessment: 2 independent outcome assessors blinded to treatment assignments according to checklist of items reported and not reported, followed by consensus Statistical analyses: Paired t-tests for the average completeness of reporting scores (primary and one secondary outcome respectively)

Results Population Forty-one masters and doctoral students participated in this study Protocol characteristics 41 different protocols -19 medications-based trials -22non pharmacological trials 9

Results: average overall scores Writing tool scores Control scores Mean difference p-value (0-10) (0-10) (95% CI) Completeness of reporting score 7.1 +/- 1.2 5.0 +/- 1.6 2.1 (1.5-2.7) <0.01 Completeness of reporting score 7.8 +/- 1.6 6.4 +/- 2.3 1.4 (0.4-2.3) 0.01 for essential elements n=41 (mean+/- s.d.) 10

Results: scores by domain Domain Writing tool scores Control tool scores Mean difference p-value* (0-10) (0-10) (95% CI) Trial design 8.1 +/- 2.3 2.7 +/- 1.9 5.4 (4.1-6.7) <0.01 Randomization 8.4 +/- 2.4 4.6 +/- 2.9 3.8 (1.1-4.4) <0.01 Blinding 6.9 +/- 2.0 6.2 +/- 2.3 0.7 (-0.7-2.0) 0.50 Participants 6.7 +/- 2.0 4.5 +/- 2.4 2.2 (0.8-3.6) <0.01 Interventions 7.1 +/- 1.5 5.3 +/- 2.0 1.8 (0.7-2.9) <0.01 Outcomes 6.1 +/- 2.1 6.4 +/- 3.0-0.3 (-2.0-1.3) 0.43 n=20 or 21 (mean +/- s.d.), *Wilcoxon tests 11

Conclusion A simple Writing Aid tool could improve of completeness of reporting Implications for future research: To expand and improve the tool to incorporate all CONSORT items and items for CONSORT extensions 12

Extra slides for explanation if necessary 13

Example: completeness of reporting score Protocol Key element to report Keyword or phrase Weight Evaluation Score Total score x Methods to generate the sequence Computer generated 1.5 Reported 1.5 7.25 Minimization 1.5 Reported 1.5 Randomization ratio 1 to 1 1 Not reported 0 Restriction method(s) Site 0.5 Reported 0.5 Visit 1 MMSE score 0.25 Not reported 0 Mild or moderate 0.25 Reported 0.25 Mechanism of allocation concealment IVRS (interactive voice response system) 3.5 Reported 3.5 Who generated the allocation sequence Who enrolled the patients and assigned the interventions Information not available: who generated the allocation sequence Information not available: who enrolled patients, who assigned the interventions 0.5 Not reported 0 0.5 Not reported 0 How the allocation list was kept secret Information not available: how the allocation list was kept secret 0.5 Not reported 0 Generic for the type of protocol Specific to the protocol 14

Example: scoring system for the completeness of reporting essential items Pharmacological therapy Essential element to report Weight TD: Type of trial design (parallel, etc) 10 Randomization: Sequence generation 5 Randomization: Allocation concealment 5 Blinding: participants 5 Blinding: outcome assessors 5 Participants: Inclusion and exclusion criteria 10 Intervention: Medication name 2.5 Intervention: Dose and duration of administration 2.5 Intervention: Number and timing of medication administration 2.5 Intervention: Name or type of control treatment 2.5 Outcomes: Presentation of primary outcome 5 Outcomes: Time frame for the primary outcome 5 15

Flowchart for selecting study protocols 16

Discussion Strengths: Randomized controlled trial Unique study protocols, describing a large variety of interventions Different types of pharmacological treatments (oral, subcutaneous, intravenous, other), strategy based treatments, surgical procedures, care support, psychotherapy, patient education and more) Real protocols Limitations: Study population not representative (students, many without experience) Context (4 hours to write, use of study protocols by other researchers) Control tool still provided structure to writer reports Protocols only representative of RCTs published in NEJM and JCO 17